Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386034822> ?p ?o ?g. }
- W4386034822 endingPage "213594" @default.
- W4386034822 startingPage "213594" @default.
- W4386034822 abstract "The rise of tuberculosis (TB) superbugs has impeded efforts to control this infectious ailment, and new treatment options are few. Paradoxical Inflammation (PI) is another major problem associated with current anti-TB therapy, which can complicate the treatment and leads to clinical worsening despite a decrease in bacterial burden in the lungs. TB infection is generally accompanied by an intense local inflammatory response which may be critical to TB pathogenesis. Clofazimine (CLF), a second-line anti-TB drug, delineated potential anti-mycobacterial effects in-vitro and in-vivo and also demonstrated anti-inflammatory potential in in-vitro experiments. However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ. To unravel these issues, nanocrystals of CLF (CLF-NC) were prepared using a microfluidizer® technology, which was further processed into micro-sized CLF nano-clusters (CLF-NCLs) by spray drying technique. This particle engineering offers combined advantages of micron- and nano-scale particles where micron-sized (~5 μm) promise optimum aerodynamic parameters for the finest lung deposition, and nano-scale dimensions (~600 nm) improve the dissolution profile of apparently insoluble clofazimine. An inhalable formulation was evaluated against virulent mycobacterium tuberculosis in in-vitro studies and in mice infected with aerosol TB infection. CLF-NCLs resulted in the significant killing of virulent TB bacteria with a MIC value of ~0.62 μg/ml, as demonstrated by Resazurin microtiter assay (REMA). In TB-infected mice, inhaled doses of CLF-NCLs equivalent to ~300 μg and ~ 600 μg administered on alternate days over 30 days significantly reduced the number of bacteria in the lung. With an inhaled dose of ~600 μg/mice, reduction of mycobacterial colony forming units (CFU) was achieved by ~1.95 Log10CFU times compared to CLF administered via oral gavage (~1.18 Log10CFU). Lung histology scoring showed improved pathogenesis and inflammation in infected animals after 30 days of inhalation dosing of CLF-NCLs. The levels of pro-inflammatory mediators, including cytokines, TNF-α & IL-6, and MMP-2 in bronchoalveolar lavage fluid (BALF) and lung tissue homogenates, were attenuated after inhalation treatment. These pre-clinical data suggest inhalable CLF-NCLs are well tolerated, show significant anti-TB activity and apparently able to tackle the challenge of paradoxical chronic lung inflammation in murine TB model." @default.
- W4386034822 created "2023-08-22" @default.
- W4386034822 creator A5003276224 @default.
- W4386034822 creator A5006595070 @default.
- W4386034822 creator A5009173365 @default.
- W4386034822 creator A5022961880 @default.
- W4386034822 creator A5044982342 @default.
- W4386034822 creator A5049060394 @default.
- W4386034822 creator A5053280142 @default.
- W4386034822 creator A5087788700 @default.
- W4386034822 date "2023-11-01" @default.
- W4386034822 modified "2023-09-26" @default.
- W4386034822 title "Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation" @default.
- W4386034822 cites W1112944074 @default.
- W4386034822 cites W2000905457 @default.
- W4386034822 cites W2003987803 @default.
- W4386034822 cites W2007508593 @default.
- W4386034822 cites W2019368210 @default.
- W4386034822 cites W2022582133 @default.
- W4386034822 cites W2071711748 @default.
- W4386034822 cites W2096040265 @default.
- W4386034822 cites W2123269282 @default.
- W4386034822 cites W2152352703 @default.
- W4386034822 cites W2193888324 @default.
- W4386034822 cites W2199646878 @default.
- W4386034822 cites W2322639880 @default.
- W4386034822 cites W2591209965 @default.
- W4386034822 cites W2765194140 @default.
- W4386034822 cites W2765883709 @default.
- W4386034822 cites W2770929776 @default.
- W4386034822 cites W2783618712 @default.
- W4386034822 cites W2793229599 @default.
- W4386034822 cites W2911005030 @default.
- W4386034822 cites W2943767932 @default.
- W4386034822 cites W2946708745 @default.
- W4386034822 cites W2989853105 @default.
- W4386034822 cites W3021612420 @default.
- W4386034822 cites W3033524992 @default.
- W4386034822 cites W3034783783 @default.
- W4386034822 cites W3082517445 @default.
- W4386034822 cites W3084818443 @default.
- W4386034822 cites W3087073121 @default.
- W4386034822 cites W3095935840 @default.
- W4386034822 cites W3112976334 @default.
- W4386034822 cites W3134691677 @default.
- W4386034822 cites W3162386143 @default.
- W4386034822 cites W3172637500 @default.
- W4386034822 cites W3200922917 @default.
- W4386034822 cites W3209908544 @default.
- W4386034822 cites W4211157605 @default.
- W4386034822 cites W4214617218 @default.
- W4386034822 cites W4214845589 @default.
- W4386034822 cites W4220832129 @default.
- W4386034822 cites W4281670909 @default.
- W4386034822 cites W4292400845 @default.
- W4386034822 cites W4313547686 @default.
- W4386034822 cites W4365448572 @default.
- W4386034822 doi "https://doi.org/10.1016/j.bioadv.2023.213594" @default.
- W4386034822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37657277" @default.
- W4386034822 hasPublicationYear "2023" @default.
- W4386034822 type Work @default.
- W4386034822 citedByCount "0" @default.
- W4386034822 crossrefType "journal-article" @default.
- W4386034822 hasAuthorship W4386034822A5003276224 @default.
- W4386034822 hasAuthorship W4386034822A5006595070 @default.
- W4386034822 hasAuthorship W4386034822A5009173365 @default.
- W4386034822 hasAuthorship W4386034822A5022961880 @default.
- W4386034822 hasAuthorship W4386034822A5044982342 @default.
- W4386034822 hasAuthorship W4386034822A5049060394 @default.
- W4386034822 hasAuthorship W4386034822A5053280142 @default.
- W4386034822 hasAuthorship W4386034822A5087788700 @default.
- W4386034822 hasConcept C142724271 @default.
- W4386034822 hasConcept C150903083 @default.
- W4386034822 hasConcept C181389837 @default.
- W4386034822 hasConcept C185592680 @default.
- W4386034822 hasConcept C202751555 @default.
- W4386034822 hasConcept C203014093 @default.
- W4386034822 hasConcept C207001950 @default.
- W4386034822 hasConcept C2776297342 @default.
- W4386034822 hasConcept C2777975735 @default.
- W4386034822 hasConcept C2780695269 @default.
- W4386034822 hasConcept C2781069245 @default.
- W4386034822 hasConcept C55493867 @default.
- W4386034822 hasConcept C71924100 @default.
- W4386034822 hasConcept C86803240 @default.
- W4386034822 hasConcept C89423630 @default.
- W4386034822 hasConcept C98274493 @default.
- W4386034822 hasConceptScore W4386034822C142724271 @default.
- W4386034822 hasConceptScore W4386034822C150903083 @default.
- W4386034822 hasConceptScore W4386034822C181389837 @default.
- W4386034822 hasConceptScore W4386034822C185592680 @default.
- W4386034822 hasConceptScore W4386034822C202751555 @default.
- W4386034822 hasConceptScore W4386034822C203014093 @default.
- W4386034822 hasConceptScore W4386034822C207001950 @default.
- W4386034822 hasConceptScore W4386034822C2776297342 @default.
- W4386034822 hasConceptScore W4386034822C2777975735 @default.
- W4386034822 hasConceptScore W4386034822C2780695269 @default.
- W4386034822 hasConceptScore W4386034822C2781069245 @default.